Onychomatricoma

Durrant, Michael N.; Palla, Beth; Binder, Scott W.

doi:10.1177/1938640011422593

Cited by 13 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[10][11][12][13][14][15] Not only can onychomatricoma be clinically misdiagnosed as onychomycosis, but concomitant fungi can also pose a histopathologic challenge. [16][17][18][19][20][21][22] This presents a diagnostic challenge as a nail clipping of an onychomatricoma may show onychomycosis, and a dermatopathologist unfamiliar with the other histopathologic features of a nail clipping from an onychomatricoma may miss the other diagnostic features. This can result in a lack of response despite appropriate antifungal therapy because an onychomatricoma may also be present (as in the case presented herein), and an excision is required to adequately remove the tumor.…”

Section: Discussionmentioning

confidence: 99%

Blue onychomatricoma: Blue discoloration of an onychomatricoma secondary to pigmented onychomycosis

Park,

Greenblatt,

Fang

et al. 2024

J Cutan Pathol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Blue onychomatricoma: Blue discoloration of an onychomatricoma secondary to pigmented onychomycosis

Park,

Greenblatt,

Fang

et al. 2024

J Cutan Pathol

View full text Add to dashboard Cite

“…The microscopy is characterized by nail bed papillomatosis within a fibrous and cellular stroma, whereas the papillomatous variant of onychocytic matricoma (the main differential) has superficial epithelial digitations that lack a connective tissue core. 5 Onychocytic carcinoma presents as an acquired localized (monodactylous) longitudinal pachyonychia. Histologically, this in situ malignant epithelial tumor exhibits cytological features of malignancy, including marked nuclear pleomorphism, prominent nucleoli, and frequent mitotic figures, many of which are abnormal.…”

Section: Discussionmentioning

confidence: 99%

Onychocytic matricoma

D'Almeida

Jeunon

Leverone

et al. 2019

An. Bras. Dermatol.

View full text Add to dashboard Cite

Onychocytic matricoma is a newly described tumor of the nail matrix. Clinically, it presents with localized thickening of the nail plate and melanonychia. Histologically, it represents a benign acanthoma of onychocytes. There are 8 cases reported in the literature. A 12-year-old girl presented with localized melanonychia and concurrent thickening of the nail plate restricted to the area of pigmentation affecting the right thumb, with no history of trauma or pain. We report a case of this rare tumor occurring in late childhood and provide a comprehensive review of its clinical presentation and differential diagnosis. Both clinicians and dermatopathologists should be aware of the presentation of onychocytic matricoma and include it in their scope of diagnosis of longitudinal nail bands.

show abstract

Onychocytic Matricoma: A New, Important Nail-Unit Tumor Mistaken for a Foreign Body

2014

View full text Add to dashboard Cite

The mechanism for voriconazole-induced photosensitivity and phototoxicity remains unknown. One current hypothesis includes a potentially phototoxic UV-B-absorbing N-oxide metabolite of voriconazole. 4 Alternatively, inhibition of CYP450 with voriconazole therapy is thought to possibly increase serum retinol level, a known photosensitizer. 5 Malignant skin conditions associated with chronic voriconazole use, including melanoma in situ and squamous cell carcinoma, have been reported in patients with Fitzpatrick skin types III or below and more commonly in individuals with some degree of immune compromise. 1,2 More recently, the development of lentigines in a dark-skinned patient receiving longterm voriconazole therapy was described. 6 Our patient is similar in the abrupt development of lentigines and photodamage characterized by mild poikiloderma but differs from the prior report owing to the severe melanocytic atypia observed. Cutaneous adverse effects of long-term voriconazole therapy are not only burdensome but also lead to morbidity and mortality. Product labeling recommends discontinuation of voriconazole therapy if a squamous cell carcinoma or melanoma develops, 1,2 which can lead to adverse outcomes if alternative antifungal therapies are limited. In addition, for patients awaiting transplant, the development of a melanoma also could compromise the ability to receive an organ donation. This report highlights the development of atypical melanocytic lesions in a dark-skinned individual receiving concurrent voriconazole and immunosuppression therapy and reinforces the importance of counseling patients on appropriate sun protection and sun avoidance. These patients, regardless of skin type, require frequent dermatologic follow-up and surveillance with a low threshold for biopsy of atypical lesions.

show abstract

Onychomatricoma

Cited by 13 publications

References 22 publications

Blue onychomatricoma: Blue discoloration of an onychomatricoma secondary to pigmented onychomycosis

Blue onychomatricoma: Blue discoloration of an onychomatricoma secondary to pigmented onychomycosis

Onychocytic matricoma

Onychocytic Matricoma: A New, Important Nail-Unit Tumor Mistaken for a Foreign Body

Contact Info

Product

Resources

About